We are live on ! Find out more
TCM

TCG Crossover Management Portfolio holdings

AUM $4.16B
1-Year Est. Return 983.43%
This Fund
S&P 500
This Quarter Est. Return
+25.75%
1 Year Est. Return
+983.43%
3 Year Est. Return
+3,012.95%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$3.5B
AUM Growth
+$474M
Cap. Flow
+$174M
Cap. Flow %
4.97%
Top 10 Hldgs %
60.94%
Holding
54
New
11
Increased
8
Reduced
10
Closed
5

Top Buys

Rank Stock Value
1
MIRM icon
Mirum Pharmaceuticals
MIRM
+$94.1M
2
IRON icon
Disc Medicine
IRON
+$93.1M
3
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$85.6M
4
VOR icon
Vor Biopharma
VOR
+$80M
5
IMVT icon
Immunovant
IMVT
+$72.4M

Top Sells

Rank Stock Value
1
RAPT
RAPT Therapeutics
RAPT
+$87.5M
2
ABVX
Abivax
ABVX
+$74.6M
3
EYPT icon
EyePoint Inc
EYPT
+$65.3M
4
GPCR icon
Structure Therapeutics
GPCR
+$53.4M
5
LQDA icon
Liquidia Corp
LQDA
+$48.5M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EYPT icon
51
EyePoint Inc
EYPT
$386M
– –
-3,572,335
Closed -$65.3M
RAPT
52
DELISTED
RAPT Therapeutics
RAPT
– –
-2,582,408
Closed -$87.5M
VTYX
53
DELISTED
Ventyx Biosciences
VTYX
– –
-316,195
Closed -$2.86M
MAZE
54
Maze Therapeutics
MAZE
$1.52B
– –
-173,816
Closed -$7.2M
1 2
3

Similar funds

GCM
Gates Capital Management New York $4.16B AUM 21% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return
CIC
Chilton Investment Company Stamford, Connecticut $4.17B AUM 1.75% 1-Year Est. Return
LWCA
Locust Wood Capital Advisers New York $4.15B AUM 31.06% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.15B AUM 13.14% 1-Year Est. Return
MSI
Mitsui Sumitomo Insurance Tokyo, Japan $4.15B AUM
CAM
Crake Asset Management London, United Kingdom $4.18B AUM 13.97% 1-Year Est. Return
JFG
JMG Financial Group Downers Grove, Illinois $4.14B AUM 21.49% 1-Year Est. Return

TCG Crossover Management's Q1 2026 Portfolio in Review

As of Q1 2026, TCG Crossover Management held 54 positions worth $3.5B, up 16% from $3.02B the previous quarter. Its ten largest holdings account for 61% of the portfolio.

TCG Crossover Management deployed $174M of net new capital in Q1 2026, opening 11 new positions and adding to 8 existing holdings. Its largest new stake was Disc Medicine: 1,341,862 shares worth $85.8M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Abivax, an estimated $74.6M trimmed.

  • TCG Crossover Management's largest Q1 2026 buy was Disc Medicine: 1,341,862 shares worth $85.8M.
  • TCG Crossover Management added most to Mirum Pharmaceuticals in Q1 2026, an estimated $94.1M increase.
  • TCG Crossover Management's biggest Q1 2026 reduction was Abivax, cutting an estimated $74.6M.
  • TCG Crossover Management fully exited RAPT Therapeutics in Q1 2026, selling an estimated $87.5M.
  • TCG Crossover Management's ten largest holdings make up 61% of its $3.5B portfolio in Q1 2026.
  • TCG Crossover Management opened 11 new positions and closed 5 in Q1 2026.
  • TCG Crossover Management's portfolio value rose 16% quarter-over-quarter to $3.5B.

Based on TCG Crossover Management's 13F filing for Q1 2026, filed 15 May 2026.